Applications of Drotaverin Hydrochloride in Industrial Manufacturing

As a leading producer, we supply Drotaverin Hydrochloride to a select range of sectors where precise formulation and regulatory adherence are critical for large-scale product development. Our production technologies ensure high consistency for demanding downstream manufacturers, supporting advanced process integration and strict compliance obligations.

1. Pharmaceutical Antispasmodic Formulations

Drotaverin Hydrochloride is a key API in manufacturing antispasmodic pharmaceuticals used in the treatment of gastrointestinal, biliary, and urinary tract disorders. Downstream, pharmaceutical manufacturers process the raw material through wet granulation or direct compression depending on the intended solid or liquid dosage form. Quality documentation, traceability, and impurity profile are mandatory at every batch to support finished product registrations in regulated and semi-regulated markets. Release testing aligns with compendial monographs, and the ingredient’s origin and control are part of mandatory regulatory inspections.

Industry compliance standards

• ICH Q7 GMP guidelines for active pharmaceutical ingredients
• European Pharmacopoeia (Ph. Eur.) monograph
• United States Pharmacopeia (USP) API specifications
• WHO GMP certificates for API export
• DMF (Drug Master File) submission where required

Typical usage ratio

• 40 mg per tablet for solid oral formulations
• 0.4% – 0.6% w/w in injectable solutions, based on product concentration
• Ratio may adjust to match regional maximum daily dose or product registration

Downstream process integration

• Introduced during dry or wet blending after API identification
• Subjected to granulation, encapsulation, or solution preparation steps
• Inline API content assay and HPLC impurity screening prior to fill-finish
• Full batch record linking API lot to each finished product batch

Final product types

• Antispasmodic tablets (oral solid dose)
• Injectable ampoules and vials
• Film-coated caplets
• Oral suspension sachets (where allowed by local health authorities)

2. Fixed-Dose Combination Drug Manufacturing

Drotaverin Hydrochloride sees extensive use in fixed-dose combination drugs, often paired with analgesics or other antispasmodics. Contract manufacturing organizations and branded generic producers develop multi-component tablets requiring precise ratio control, segregation of active blend steps, and robust release documentation. Downstream manufacturers depend on detailed process validation and control to ensure no cross-contamination and the correct blending of each active. Full traceability and compliance with each combination’s registration dossier are required, making the supply of this raw material an integral step in the production schedule.

Industry compliance standards

• EMA guideline on fixed-combination medicinal products
• Schedule M of Indian GMP rules (for local and export production)
• Periodical validation and cleaning protocol records
• Pharmacopeial compliance for each combined API

Typical usage ratio

• 20–80 mg per tablet/capsule, standardized to match co-formulant strength (e.g., paracetamol)
• Combinatory ratios based on final approved blend documented in ANDA/NDA/MA dossiers

Downstream process integration

• Staged weighing and separate milling of all actives
• Controlled sequencing of Drotaverin addition during blending
• Dedicated blending lines for high-potency APIs
• Comprehensive IPC (in-process control) including blend uniformity and cross-contaminant analysis

Final product types

• Antispasmodic-analgesic fixed dose combination tablets
• Multi-layered caplets
• Blister-packed poly-pill forms for hospital and retail supply

3. Contract API Finished Dose Export Manufacturing

Export-oriented contract formulation plants operating under strict international GMP depend on Drotaverin Hydrochloride as a core input for producing finished formulations destined for regulated and semi-regulated markets. These manufacturing units run large-volume blending lines, focusing on regulatory documentation, batch release protocols, and impurity limits in line with target market registration. Supply traceability, validated cleaning, and adherence to import/export pharmacopoeial standards are mandatory at every stage. Our production ensures detailed batch documentation and on-demand quality data for all shipments.

Industry compliance standards

• US FDA cGMP (21 CFR Part 210/211) for finished pharmaceutical manufacturers
• ANVISA requirements (for Brazil exports)
• EDQM CEP documentation (when required for EU market)
• Local GMP inspection and product-specific QC protocols (Saudi FDA, Russia, TGA, etc.)

Typical usage ratio

• Standardized as 1:1 to 1:2 w/w with co-active agents in dosage forms
• 2–12% of total batch per finished product, depending on form factor and recipe
• Ratio fine-tuned to local pharmacopeial maximum active thresholds

Downstream process integration

• Material intake, sampling, and QC on arrival from raw material warehouse
• Batch blending under HEPA or contained rooms
• Process monitoring to ensure content uniformity during granulation/compression
• Batch record and product traceability for each export lot

Final product types

• Bulk oral solid dose tablets for contract export
• Finished ampoules/sterile vials for parenteral export
• Customized private-label blends for regional distributors

4. Veterinary Antispasmodic Drug Production

Drotaverin Hydrochloride is included in select veterinary antispasmodic medications for livestock and companion animals. Veterinary pharmaceutical plants formulate the active into injectable and oral dosage forms, following species-specific dosing requirements and regional veterinary product regulations. Each production batch undergoes extensive residue and identity testing, with documentation ensuring full traceability. Manufacturers must comply with animal pharmacopoeia monographs where available, and validated cleaning is mandated to prevent cross-species contamination risk.

Industry compliance standards

• VICH GL guidelines for veterinary APIs
• WHO GMP for veterinary drugs
• National Veterinary Drug Regulator (e.g., India’s CVCP, European Union’s CVMP)
• Veterinary Pharmacopoeia entries (where defined)

Typical usage ratio

• 5–20 mg/mL in injectable solutions, adjusted for weight and species as per product dossier
• 0.2–0.5% w/w in oral veterinary premixes, regularly reviewed against permitted maximums

Downstream process integration

• Transfer from raw material store under batch quarantine
• Formulation with buffers and stabilizers in animal health production lines
• Cross-checking for species appropriateness at formulation stage
• Residue testing and product sterility assessment before final fill

Final product types

• Veterinary injectable vials for farm animal use
• Oral suspension packs for equine/canine application
• Pre-mixed feed additives where approved